Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-morpholin-4-yl-9H-purine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
A synthetic small molecule purine derivative featuring a morpholine group at the C6 position of the purine ring. It is primarily studied as an experimental compound and is not approved for clinical use. Its main mechanism of action is inhibition of serine/threonine-protein kinase Chk1, a key regulator in cell cycle checkpoint control and DNA damage response pathways. The compound has been investigated in structural biology studies as a Chk1 inhibitor, but there are no reported clinical trials or approved indications[1][2][7].
- Other names
- 6-MORPHOLIN-4-YL-9H-PURINE6-(morpholin-4-y)-9h-purine2846–96–0 (CAS)C9H11N5O (molecular formula)CHK1_HUMAN (target-related synonym)
02
Targets
CHEK1 (Checkpoint kinase 1)
Beyond the preview
Go deeper on 6-morpholin-4-yl-9H-purine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-morpholin-4-yl-9H-purine.